PTO:SB96 (01-06)
Approved for use through 043 7/2018 CMS 0935-9803
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMISSION OF U.S. DEPARTMENT OF U.S. D

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: Alphama Inc.	
Application No./Patent No.: 10/667,570	Filed/Issue Date: 09/22/2003
Entitled: Sustained Reloase Optoid Formulations and Meth	thous of Use
Alpharma, inc. (Name of Assignes)	, 8carporation
states that it is:  1.  the assignee of the entire right, title, and interest	st; or
an assignee of less than the entire right, title an (The extent (by percentage) of its ownership interpretations)	
in the patent application/patent identified above by virt	rtue of either:
A An assignment from the inventor(s) of the paten in the United States Patent and Trademark Offic thereof is attached.	nt application/patent identified above. The assignment was recorded ce at Reel <u>014833</u> , Frame <u>0288</u> or for which a copy
OR	nt application/patent identified above, to the current assignee as follows:
The document was recorded in the Unite Reel Frame_  2. From:	To:  ed States Patent and Trademark Office at or for which a copy thereof is attached.  To:
The document was recorded in the Units	ed States Patent and Trademark Office at or for which a copy thereof is attached.
3. From:	To: ed States Patent and Trademark Office at
Reel Frame	ed States Patent and Trademark Office at, or for which a copy thereof is attached.
Additional documents in the chain of title are	e listed on a supplemental sheet.
As required by 37 CFR 3.73(b)(1)(i), the docume assignee was, or concurrently is being, submitted for its	entary evidence of the chain of title from the original owner to the recordation pursuant to 37 CFR 3.11.
	original assignment document(s)) must be submitted to Assignment to record the assignment in the records of the USPTO. <u>See MPEP</u>
The undersigned (whose title is supplied below) is aut	thorized to sot on behalf of the assignee.
	(deales
Signature	Date
Shah R. Makujina	508-566-4108
Printed or Typed Name	Telephone Number
Vice President, Chief Patent Counsel,	Alpharma, inc.

This collection of information is required by 37 CFR 3.75g. The information is required to obtain or retain is benefit by the poblic which is to fire (and by the LISPTO to process) an application. Confinentiality is oper